IL17A and cystic fibrosis: Different from JA or UA monotherapy, in the top 10 pathways altered in JU treatment, 5 were related to development processes and 2 to transcription, and others were involved in signal transdection, Mucin expression in CF via interleukin 6 (IL-6), IL-17 signaling pathways, and regulation of CFTR activity.